I’M A

LIAR

Telling everyone I'm fine when
that's far from the truth.

Telling everyone I'm fine when that's far from the truth.

For certain adults with HER2-positive or HER2-low metastatic breast cancer (mBC) who have received prior treatment for mBC^*

ENHERTU helped people live longer than other medicines.

Clinical trial results:
HER2-positive mBC: At the time of data analysis, 65% of people on ENHERTU were alive vs 52% on ado-trastuzumab emtansine.^†
HER2-low mBC: People on ENHERTU lived a median of 23 months vs 17 months on chemotherapy.^‡

Metastatic is defined as cancer that has spread to other parts of the body.

^*Prior mBC treatments include anti-HER2 therapy for HER2-positive and chemotherapy for HER2-low.

^†A median is the middle number in a set of numbers. Median duration of follow-up for ENHERTU was 28.4 months and 26.5 months for ado-trastuzumab emtansine.

^‡Median duration of follow-up was 18.4 months.

Not an actual patient.

Not an actual patient.

I’M A

CHEATER

But not like you think. I'm tricking
my metastatic breast cancer.

But not like you think. I'm tricking my metastatic breast cancer.

For certain adults with HER2-positive or HER2-low metastatic breast cancer (mBC) who have received prior treatment for mBC^*

ENHERTU helped people live longer than other medicines.

Clinical trial results:
HER2-positive mBC: At the time of data analysis, 65% of people on ENHERTU were alive vs 52% on ado-trastuzumab emtansine.^†
HER2-low mBC: People on ENHERTU lived a median of 23 months vs 17 months on chemotherapy.^‡

Metastatic is defined as cancer that has spread to other parts of the body.

^*Prior mBC treatments include anti-HER2 therapy for HER2-positive and chemotherapy for HER2-low.

^†A median is the middle number in a set of numbers. Median duration of follow-up for ENHERTU was 28.4 months and 26.5 months for ado-trastuzumab emtansine.

^‡Median duration of follow-up was 18.4 months.

Not an actual patient.

Not an actual patient.

I’M A

THIEF

I'm stealing more moments.
More glimpses. More kisses.

I'm stealing more moments. More glimpses. More kisses.

For certain adults with HER2-positive or HER2-low metastatic breast cancer (mBC) who have received prior treatment for mBC^*

ENHERTU helped people live longer than other medicines.

Clinical trial results:
HER2-positive mBC: At the time of data analysis, 65% of people on ENHERTU were alive vs 52% on ado-trastuzumab emtansine.^†
HER2-low mBC: People on ENHERTU lived a median of 23 months vs 17 months on chemotherapy.^‡

Metastatic is defined as cancer that has spread to other parts of the body.

^*Prior mBC treatments include anti-HER2 therapy for HER2-positive and chemotherapy for HER2-low.

^†A median is the middle number in a set of numbers. Median duration of follow-up for ENHERTU was 28.4 months and 26.5 months for ado-trastuzumab emtansine.

^‡Median duration of follow-up was 18.4 months.

Not an actual patient.

Not an actual patient.

Sure, metastatic
breast cancer will
try to take it all. But

Sure, metastatic breast cancer will try to take it all. But

NOT TODAY NOT TODAY

For certain adults with HER2-positive or HER2-low metastatic breast cancer (mBC) who have
received prior treatment for mBC^*

ENHERTU helped people live longer than other medicines.

Clinical trial results:
HER2-positive mBC: At the time of data analysis, 65% of people on ENHERTU were alive vs 52% on ado-trastuzumab emtansine.^†
HER2-low mBC: People on ENHERTU lived a median of 23 months vs 17 months on chemotherapy.^‡

Metastatic is defined as cancer that has spread to other parts of the body.

^*Prior mBC treatments include anti-HER2 therapy for HER2-positive and chemotherapy for HER2-low.

^†A median is the middle number in a set of numbers. Median duration of follow-up for ENHERTU was 28.4 months and 26.5 months for ado-trastuzumab emtansine.

^‡Median duration of follow-up was 18.4 months.

Not an actual patient.

Not an actual patient.

For certain adults with HER2-positive or HER2-low metastatic breast cancer (mBC) who have received prior treatment for mBC^*

ENHERTU helped people live longer than other medicines.

Clinical trial results:
HER2-positive mBC:
At the time of data analysis, 65% of people on ENHERTU were alive vs 52% on ado-trastuzumab emtansine.^†
HER2-low mBC:
People on ENHERTU lived a median of 23 months vs 17 months on chemotherapy.^‡

Metastatic is defined as cancer that has spread to other parts of the body.

^*Prior mBC treatments include anti-HER2 therapy for HER2-positive and chemotherapy for HER2-low.

^†A median is the middle number in a set of numbers. Median duration of follow-up for ENHERTU was 28.4 months and 26.5 months for ado-trastuzumab emtansine.

^‡Median duration of follow-up was 18.4 months.

Learn how ENHERTU may help people with these types of mBC:

HER2-positive mBC

ENHERTU is a prescription medicine used to treat adults who have HER2-positive breast cancer that cannot be removed by surgery or that has spread to other parts of the body (metastatic), and who have received a prior anti-HER2 breast cancer treatment for metastatic disease or have breast cancer that has come back during or within 6 months of completing treatment for their early-stage breast cancer.

HER2-low mBC

ENHERTU is a prescription medicine used to treat adults who have HER2-low breast cancer that cannot be removed by surgery or that has spread to other parts of your body (metastatic), and who have received a prior chemotherapy for metastatic disease, or whose disease has returned during or within 6 months of completing adjuvant chemotherapy (after surgery). Your healthcare provider will perform a test to make sure ENHERTU is right for you.

If you were diagnosed with HER2-negative mBC, you may actually have low levels of HER2.

Understanding low levels of HER2

Learn more about other approved uses for ENHERTU

HER2, human epidermal growth factor receptor 2; mBC, metastatic breast cancer.

Important Safety Information (including Boxed WARNINGS)

What is the most important information I should know about ENHERTU?
ENHERTU can cause serious side effects, including:

Lung problems that may be severe, life-threatening or that may lead to death. If you develop lung problems your healthcare provider may treat you with corticosteroid medicines. Tell your healthcare provider right away if you get any of the following signs and symptoms:
- Cough
- Trouble breathing or shortness of breath
- Fever
- Other new or worsening breathing symptoms (such as chest tightness, wheezing)
Low white blood cell count (neutropenia). Low white blood cell counts are common with ENHERTU and can sometimes be severe. Your healthcare provider will check your white blood cell counts before starting ENHERTU and before starting each dose. Tell your healthcare provider right away if you develop any signs or symptoms of an infection or have fever or chills during treatment with ENHERTU.
Heart problems that may affect your heart's ability to pump blood. Your healthcare provider will check your heart function before starting treatment with ENHERTU. Tell your healthcare provider right away if you get any of the following signs and symptoms:
- New or worsening shortness of breath
- Coughing
- Feeling tired
- Swelling of your ankles or legs
- Irregular heartbeat
- Sudden weight gain
- Dizziness or feeling light-headed
- Loss of consciousness

Your healthcare provider will check you for these side effects during your treatment with ENHERTU. Your healthcare provider may reduce your dose, delay treatment or completely stop treatment with ENHERTU if you have severe side effects.

Harm to your unborn baby. Tell your healthcare provider right away if you become pregnant or think you might be pregnant during treatment with ENHERTU.
- If you are able to become pregnant, your healthcare provider should do a pregnancy test before you start treatment with ENHERTU.
- Females who are able to become pregnant should use effective birth control (contraception) during treatment with ENHERTU and for 7 months after the last dose.
- Males who have female partners that are able to become pregnant should use effective birth control (contraception) during treatment with ENHERTU and for 4 months after the last dose.

Before you receive ENHERTU, tell your healthcare provider about all of your medical conditions, including if you:

Have lung or breathing problems.
Have signs or symptoms of an infection.
Have or have had any heart problems.
Are breastfeeding or plan to breastfeed. It is not known if ENHERTU passes into your breast milk. Do not breastfeed during treatment with ENHERTU and for 7 months after the last dose.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

How will I receive ENHERTU?

You will receive ENHERTU into your vein through an intravenous (IV) line by your healthcare provider.
ENHERTU is given 1 time every three weeks (21-day treatment cycle).
Your healthcare provider will decide how many treatments you need.
Your healthcare provider will give you medicines before your infusion to help prevent nausea and vomiting.
Your healthcare provider may slow down or temporarily stop your infusion of ENHERTU if you have an infusion-related reaction, or permanently stop ENHERTU if you have severe infusion reactions.
If you miss a planned dose of ENHERTU, call your healthcare provider right away to schedule an appointment. Do not wait until the next planned treatment cycle.

What are the possible side effects of ENHERTU?

ENHERTU can cause serious side effects. See "What is the most important information I should know about ENHERTU?"

The most common side effects of ENHERTU when used at the 5.4 mg/kg dose include:

Low white blood cell counts
Nausea
Low red blood cell counts
Feeling tired
Low platelet counts
Increased liver function tests
Vomiting

Hair loss
Constipation
Low levels of blood potassium
Decreased appetite
Diarrhea
Muscle or bone pain

ENHERTU may cause fertility problems in males, which may affect the ability to father children. Talk to your healthcare provider if you have concerns about fertility.

These are not all of the possible side effects of ENHERTU. Call your doctor for medical advice about side effects. You may report side effects to Daiichi Sankyo at 1-877-437-7763 or to FDA at 1-800-FDA-1088.

What is ENHERTU?
ENHERTU is a prescription medicine used to treat adults who have:

Human epidermal growth factor receptor 2 (HER2)-positive breast cancer that cannot be removed by surgery or that has spread to other parts of the body (metastatic), and who have received a prior anti-HER2 breast cancer treatment:
- for metastatic disease, or
- have breast cancer that has come back during or within 6 months of completing treatment for their early-stage breast cancer.
HER2-low breast cancer that cannot be removed by surgery or that has spread to other parts of the body (metastatic), and who have received a prior chemotherapy
- for metastatic disease, or
- whose disease has returned during or within 6 months of completing adjuvant chemotherapy (after surgery).
Hormone receptor (HR)-positive, HER2-low or HR-positive, HER2-ultralow, breast cancer that cannot be removed by surgery or that has spread to other parts of the body (metastatic), and who have received one or more endocrine treatments for metastatic disease.
Your healthcare provider will perform a test to make sure ENHERTU is right for you.

It is not known if ENHERTU is safe and effective in children.

Please see full Prescribing Information, including Boxed WARNINGS, and Medication Guide.

What is ENHERTU?
ENHERTU is a prescription medicine used to treat adults who have:

Human epidermal growth factor receptor 2 (HER2)-positive breast cancer that cannot be removed by surgery or that has spread to other parts of the body (metastatic), and who have received a prior anti-HER2 breast cancer treatment:
- for metastatic disease, or
- have breast cancer that has come back during or within 6 months of completing treatment for their early-stage breast cancer.
HER2-low breast cancer that cannot be removed by surgery or that has spread to other parts of the body (metastatic), and who have received a prior chemotherapy
- for metastatic disease, or
- whose disease has returned during or within 6 months of completing adjuvant chemotherapy (after surgery).
Hormone receptor (HR)-positive, HER2-low or HR-positive, HER2-ultralow, breast cancer that cannot be removed by surgery or that has spread to other parts of the body (metastatic), and who have received one or more endocrine treatments for metastatic disease.
Your healthcare provider will perform a test to make sure ENHERTU is right for you.

It is not known if ENHERTU is safe and effective in children.